Latest news with #BrianDavidson
Fashion Value Chain
25-06-2025
- Business
- Fashion Value Chain
Nikwax 2025 Report Shows 11% Emissions Cut, New Formula
Nikwax, renowned for its eco-conscious waterproofing and gear care solutions, has unveiled its 2025 Sustainability Report, marking a significant stride toward its environmental commitments. The brand reported an 11% reduction in total carbon emissions this year, bolstered by increased adoption of renewable energy sources and a reformulation of its best-selling product—Down Wash. The upgraded Down Wash offers a 40% lower carbon footprint, superior cleaning power, and improved performance in restoring water repellency and insulation in down-filled items. 'We're proud of what we've accomplished, but we're even more excited about what lies ahead,' said Brian Davidson, CEO of Nikwax. 'Our Down Wash reformulation is a prime example of how high-performance can align with environmental care.' A trailblazer in sustainable innovation since 1977, Nikwax continues its PFAS-free, aerosol-free legacy, while collaborating with organizations like the European Outdoor Group, The Conservation Alliance, and World Land Trust. With its 2040 net-zero goal on track, Nikwax's latest report underscores that sustainability and performance can go hand-in-hand. Read the full report:
Business Wire
17-06-2025
- Health
- Business Wire
Mursla Bio Introduces AI Precision Medicine Platform Built on Organ-Specific EV Isolation from Blood
CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Mursla Bio, a leader in Extracellular Vesicle (EV) science on a mission to advance precision diagnostics and significantly improve cancer outcomes for at-risk patients, today announced the commercial launch of its AI Precision Medicine Platform, alongside a pre-print¹ reporting the first validated method for isolating hepatocyte EVs from plasma for organ-specific proteomic and miRNA profiling. Mursla Bio is engaging with potential partners to apply its Platform to additional disease areas, biomarker discovery and IVD translation programs. The Platform addresses a major gap in liquid biopsy and precision medicine: enabling non-invasive access to organ-specific molecular information from blood with high spatial and biological resolution. Mursla Bio's Platform is built on its ability to isolate and analyze EVs which are secreted by specific organs into the bloodstream. The Platform reduces non-target background by up to five orders of magnitude compared to standard bulk EV isolation and significantly improves data structure, enhancing prediction model generalization. The pre-print presents the first multi-layered validation of hepatocyte EV isolation in humans, confirming liver origin through proteomic and nucleic acid markers. Key supporting proteomics data was generated in collaboration with Evotec International GmbH. Patient samples were provided by University College London, with Professor Brian Davidson, a global leader in liver disease surgery and clinical research, contributing as a co-author. The study shows that Mursla Bio's method yields robust, organ-specific multi-omics data using minimal blood volume, offering a novel scalable approach for biomarker and AI development. Mursla Bio's Platform incorporates optimized multi-omics workflows, embedded AI pipelines, and IVD translation processes to convert complex biological signals into practical, regulatory-grade assays. These assays are deployable on standard commercial instruments using patented, PCR and ELISA-like steps designed for clinical adoption. The Platform also underpins the development of EvoLiver™, the Company's lead clinical program for liver cancer surveillance in cirrhotic patients. Built on multi-omics data from over 300 patients, EvoLiver achieved 86% sensitivity and 88% specificity on a locked, IVD-compatible assay for early-stage hepatocellular carcinoma detection², and has received Breakthrough Device Designation from the FDA³. Pierre Arsène, Founder and CEO of Mursla Bio, said: "EVs are nature's native signal enrichment system for long-distance communication between cells and organs. Our platform harnesses this biology to non-invasively access organ-specific, multi-omics data from just a small blood sample. It produces structured, biologically labeled datasets that are optimized for AI and ready to support diagnostic translation. EvoLiver is our first proof point of real-world clinical impact, and we are now expanding access to the platform to advance our pipeline and enable partnerships across other disease areas.' Mursla Bio is expanding its pipeline and collaborations, with additional organ programs underway in cardiometabolic, lung, and neurological indications. The Platform will support pharma development through dynamic patient stratification, therapeutic response monitoring, surrogate markers and molecular phenotyping across complex disease biology. For further information on Mursla Bio's AI Precision Medicine Platform, please visit
Associated Press
29-05-2025
- Business
- Associated Press
Flow Capital Announces a US$5.0 Million Investment in Congruity 360
TORONTO, May 29, 2025 (GLOBE NEWSWIRE) -- Flow Capital Corp. (TSXV:FW) ('Flow Capital' or the 'Company') is pleased to announce the successful closing of a US$5.0 million senior note investment in Congruity 360, a leading provider of unstructured data management and risk mitigation solutions. Congruity 360's Classify360 platform equips organizations with critical capabilities to understand, manage, and secure petabyte-scale unstructured data across cloud, SaaS, and on-premises environments. Its capabilities include data discovery and classification, identification of governance and compliance vulnerabilities, and automated workflows for remediation and infrastructure optimization. Already trusted by Fortune 500 companies operating across the globe, Congruity 360 will use the capital to fuel continued product innovation and growth. 'The unstructured data management and classification market is thriving! We were impressed by Congruity 360's market and product momentum, particularly its automated governance workflow and the introduction of AI into the classification process,' said Alex Baluta, CEO of Flow Capital. 'Given its high growth rate, Flow's covenant-light, founder-friendly capital was a perfect fit for Congruity 360's needs.' '2025's wins have accelerated our product and GTM plans! We are excited to partner with Flow Capital,' said Brian Davidson, CEO of Congruity 360. Technology companies seeking flexible growth capital are invited to apply for funding directly at About Congruity 360 Congruity 360 delivers the only data management solution built on a foundation of classification, by experts in data storage and data privacy. The Classify360 platform is easy to implement, requires no outside consultants, and quickly analyzes and remediates your data at a petabyte scale in days, not weeks or months. About Flow Capital Flow Capital Corp. is a publicly listed provider of flexible growth capital and alternative debt solutions dedicated to supporting high-growth companies. Since its inception in 2018, the company has provided financing to businesses in the US, the UK, and Canada, helping them achieve accelerated growth without the dilutive impact of equity financing or the complexities of traditional bank loans. Flow Capital focuses on revenue-generating, VC-backed, and founder-owned companies seeking $2 to $10 million in capital to drive their continued expansion. Learn more at For further information, please contact: Flow Capital Corp. Alex Baluta Chief Executive Officer [email protected] 47 Colborne Street, Suite 303, Toronto, Ontario M5E 1P8 Forward-Looking Information and Statements Certain statements herein may be 'forward-looking' statements that involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Flow or the industry to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Forward-looking statements involve significant risks and uncertainties, should not be read as guarantees of future performance or results, and will not necessarily be accurate indications of whether such results will be achieved. A number of factors could cause actual results to vary significantly from the results discussed in the forward-looking statements. These forward-looking statements reflect current assumptions and expectations regarding future events and operating performance and are made as of the date hereof and Flow assumes no obligation, except as required by law, to update any forward-looking statements to reflect new events or circumstances.
